At a recent international roundtable, experts from China, Germany, and Japan shared their perspectives on the TALENT study, which evaluated the combination of TACE with atezolizumab and bevacizumab for patients with unresectable intermediate to high tumor burden hepatocellular carcinoma (HCC).
Professor Guohong Han (Xi’an International Medical Center Hospital), Assistant Professor Christine Koch (University Hospital Frankfurt), Professor Haekwang Shin (Ruijin Hospital, Shanghai Jiao Tong University), and Professor Christoph Roderburg (University Hospital Essen) highlighted how this combination showed statistically significant improvements in PFS and overall response rates, with a manageable safety profile.
The discussion emphasized the synergy between local and systemic therapy, the role of the tumor microenvironment, and the potential for conversion therapy in select patients. With consistent findings across different regions, the TALENT study may influence treatment guidelines and redefine care for intermediate-stage HCC.
